Bicara Therapeutics (NASDAQ:BCAX) Now Covered by Wedbush

Wedbush started coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research report sent to investors on Thursday morning, MarketBeat reports. The brokerage issued an outperform rating and a $31.00 price objective on the stock.

BCAX has been the subject of several other reports. HC Wainwright raised their target price on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating and a $48.00 target price on the stock. Finally, RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Bicara Therapeutics has a consensus rating of “Buy” and a consensus price target of $41.20.

Bicara Therapeutics Trading Down 0.9 %

BCAX opened at $12.60 on Thursday. Bicara Therapeutics has a twelve month low of $11.10 and a twelve month high of $28.09. The stock’s 50-day simple moving average is $16.00.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). Equities analysts predict that Bicara Therapeutics will post -2.59 EPS for the current year.

Institutional Investors Weigh In On Bicara Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. acquired a new stake in Bicara Therapeutics in the 3rd quarter valued at approximately $177,169,000. FMR LLC acquired a new stake in shares of Bicara Therapeutics in the third quarter valued at $57,913,000. Braidwell LP acquired a new stake in shares of Bicara Therapeutics in the third quarter valued at $42,219,000. Janus Henderson Group PLC purchased a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at $30,329,000. Finally, Baker BROS. Advisors LP acquired a new position in Bicara Therapeutics during the 3rd quarter worth about $21,225,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.